Translational Research Award – Applications due on January 31, 2024!

Career Development Award – Applications due on January 31, 2024!

Upcoming Events

20th IMS Annual Meeting

20th IMS Annual Meeting

September 27 - December 31, 2023 - Virtual Extended Access available until December 31!

Thank you!

Thank you to all who made our 20th Annual Meeting in Athens such a success.

IMS 2023 Closing video 2nd draft 1080p from Corporate Event Images on Vimeo.

FDA-IMS Joint Workshop: Defining Patient Populations for Clinical Trials in Multiple Myeloma

FDA-IMS Joint Workshop: Defining Patient Populations for Clinical Trials in Multiple Myeloma

February 22, 2024 - The Hyatt Regency Bethesda, Maryland and Virtual

Outcomes for patients with multiple myeloma have improved with approval of several therapies. Despite this MM, remains incurable. Recent results have also highlighted the heterogeneity in outcomes in patients with multiple myeloma. Improved understanding of the clinical and disease specific prognostic factors and the availability of multiple classes of therapies has necessitated discussions on patient populations for evaluation in clinical trials of novel therapies. Additionally, as new therapies are moved into earlier lines, it is important to evaluate the appropriateness of the control arms for clinical trials.

This workshop is intended to discuss disease setting considerations in MM, with a focus on defining patient populations for enrollment onto clinical trials for MM. This meeting will bring together representatives from the physician community, patients, pharmaceutical industry and regulatory scientists.

Goals and Objectives
– Discuss eligibility criteria for MM clinical trials in different disease settings
– Discuss considerations in defining patient populations
– Review common goals and methods for clinical trial conduct

5th Immune Effector Cell Therapies in Multiple Myeloma Workshop

5th Immune Effector Cell Therapies in Multiple Myeloma Workshop

March 23 - 24, 2024 - Boston Marriott Long Wharf, Boston, MA

IMS is pleased to announce that the 5th Annual Immune Effector Cell Therapies in Multiple Myeloma Workshop will take place from March 23-24, 2024 in Boston, MA.

 

 

Tentative Agenda

Practical Insights in Novel Immune Therapies in Multiple Myeloma Webinar – East Coast

Practical Insights in Novel Immune Therapies in Multiple Myeloma Webinar – East Coast

March 27, 2024 - Webinar

Are you a hematologist or oncologist treating patients with multiple myeloma?
If so, this 90-minute webinar is for you!

This high-impact, 90-minute educational program seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engages, and CAR T therapies among healthcare professionals.

Practical Insights in Novel Immune Therapies in Multiple Myeloma Webinar – West Coast

Practical Insights in Novel Immune Therapies in Multiple Myeloma Webinar – West Coast

April 10, 2024 - Webinar

Are you a hematologist or oncologist treating patients with multiple myeloma?
If so, this 90-minute webinar is for you!

This high-impact, 90-minute educational program seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engages, and CAR T therapies among healthcare professionals.

Educational Workshop, Buenos Aires, Argentina

Educational Workshop, Buenos Aires, Argentina

April 19 - 20, 2024 - Sheraton Buenos Aires & Convention Center, Buenos Aires, Argentina

Join us for a dynamic educational workshop on the diagnosis, treatment, and monitoring of plasma cell malignancies, including current practices and opportunities for improvement. This workshop will include lectures plus roundtable discussions around hot and controversial topics, featuring point-counterpoint conversations between invited speakers and local hematologists based on both challenging questions and clinical cases.

 

Preliminary Agenda

21st IMS Annual Meeting

21st IMS Annual Meeting

September 25 - 28, 2024 - Rio de Janeiro, Brazil

Mark your calendars for the 21st IMS Annual Meeting in Rio de Janeiro, Brazil!

The 21st IMS Annual Meeting will take place in Rio de Janeiro, Brazil from September 25-28, 2024.

More details will be available soon. 

Why apply for the Career Development Award?

 

Coming soon! – ARTEMIS

Analytic Research and daTa Exchange for Myeloma International Studies

Recommendations for the Management of Myeloma Patients During the COVID-19 Pandemic

As a response to the current pandemic, the International Myeloma Society Executive Committee has developed the following Recommendations for the Management of Myeloma Patients During the COVID-19 Pandemic. These recommendations include directions for caring for newly diagnosed, elderly, relapsed/refractory and clinical trial patients. Please follow as appropriate for your practice and patient needs. The International Myeloma Society remains committed to keeping patients and physicians safe while providing care and treatment under these extraordinary circumstances.

About Our Publications

As a response to the current pandemic, the International Myeloma Society Executive Committee has developed the following Recommendations for the Management of Myeloma Patients During the COVID-19 Pandemic. These recommendations include directions for caring for newly diagnosed, elderly, relapsed/refractory and clinical trial patients. Please follow as appropriate for your practice and patient needs. The International Myeloma Society remains committed to keeping patients and physicians safe while providing care and treatment under these extraordinary circumstances.

See All Publications

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events